Choon, Siew Eng
Navarini, Alexander A.
Pinter, Andreas
Funding for this research was provided by:
Boehringer Ingelheim (The medical writing was funded by Boehringer Ingelheim)
Article History
Accepted: 28 October 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: Siew Eng Choon has received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB. Alexander Navarini has served as a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, Biomed, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi, and UCB. Andreas Pinter has served as an advisor and/or speaker and/or received grants and/or served as an investigator for AbbVie, Almirall Hermal, Amgen, Biogen, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Eli Lilly, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough, and UCB.
: Not applicable.
: Not applicable.
: Patients provided their consent to publish their cases. The authors (SEW and AP) express their gratitude to their patients for providing consent.
: Not applicable.
: Not applicable.
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.